Voluntary Recall of the "BabySenseTM" Apnea Alarm and Related Losses
First written in FY2019-Q1. 3 of 7 entries say "Worsened", first in FY2019-Q2. Latest entry: FY2021.
JCR Pharmaceuticals moved to the "Worse" side of this theme in 2018, 2 years before the typical company in this theme (2020).
The whole theme swung hardest in 2024: 3 of 6 companies on the "Worse" side.
8 other companies' latest entry also says "Mitigated".
- FY2021MitigatedAnnual report
「Reversal of voluntary recall-related losses 19」
The company recorded a ¥19 million reversal of BabySenseTM voluntary recall-related losses in the current consolidated fiscal year. - FY2020MitigatedAnnual report
「Voluntary Recall-Related Losses」
The ¥181 million in voluntary recall-related losses recorded in the previous fiscal year was not recorded in the current consolidated fiscal year. The impact of the recall issue on profit and loss for the current fiscal year declined from the previous fiscal year. - FY2020-Q1MitigatedAnnual report
「Net income attributable to owners of the parent increased by ¥86 million year on year to ¥369 million, as no medical-device voluntary recall-related losses were recorded in the current first-quarter consolidated cumulative period, unlike in the same period of the previous year.」
The company stated that the voluntary recall-related losses incurred in the same period of the previous year did not occur in the current first quarter, reducing the impact of those losses in the quarter. - FY2019WorsenedAnnual report
「Special losses amounted to ¥221 million, an increase of ¥195 million from the previous consolidated fiscal year, due in part to the voluntary recall-related losses.」
The company recorded special losses, including ¥181 million in BabySenseTM voluntary recall-related losses, bringing the losses associated with the recall issue into the full-year results. - FY2019-Q3WorsenedAnnual report
「The company recorded ¥178 million in special losses as voluntary recall-related losses for the total costs expected to arise in connection with the voluntary recall of the BabySenseTM apnea monitor announced on 25 June 2018.」
The estimated costs related to the BabySenseTM voluntary recall increased from ¥174 million in the previous quarter to ¥178 million. - FY2019-Q2WorsenedAnnual report
「The company recorded ¥174 million in special losses as voluntary recall-related losses for the total costs expected to arise in connection with the voluntary recall of the BabySenseTM apnea monitor announced on 25 June 2018.」
The estimated costs related to the BabySenseTM voluntary recall increased from ¥172 million in the first quarter to ¥174 million. - FY2019-Q1MaterialisedAnnual report
「The company recorded ¥172 million in special losses for the total costs expected to arise in connection with the voluntary recall of the BabySenseTM apnea monitor announced on 25 June of this year.」
The company announced the voluntary recall of the BabySenseTM apnea monitor on 25 June 2018 and recorded ¥172 million in special losses for the total costs expected to arise in connection with the recall.